EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells

Cancer cells acquire essential characteristics for metastatic dissemination through the process of epithelial-to-mesenchymal transition (EMT), which is regulated by gene expression and chromatin remodeling changes. The enhancer of zeste homolog 2 (EZH2), the catalytic subunit of the polycomb repressive complex 2 (PRC2), catalyzes trimethylation of lysine 27 of histone H3 (H3K27me3) to repress gene transcription. Here we report the functional roles of EZH2-catalyzed H3K27me3 during EMT in ovarian cancer (OC) cells. TGF-β-induced EMT in SKOV3 OC cells was associated with decreased levels of EZH2 and H3K27me3 (P<0.05). These effects were delayed (~72 h relative to EMT initiation) and coincided with increased (>15-fold) expression of EMT-associated transcription factors ZEB2 and SNAI2. EZH2 knockdown (using siRNA) or enzymatic inhibition (by GSK126) induced EMT-like changes in OC cells. The EMT regulator ZEB2 was upregulated in cells treated with either approach. Furthermore, TGF-β enhanced expression of ZEB2 in EZH2 siRNA- or GSK126-treated cells (P<0.01), suggesting that H3K27me3 plays a role in TGF-β-stimulated ZEB2 induction. Chromatin immunoprecipitation assays confirmed that TGF-β treatment decreased binding of EZH2 and H3K27me3 to the ZEB2 promoter (P<0.05). In all, these results demonstrate that EZH2, by repressing ZEB2, is required for the maintenance of an epithelial phenotype in OC cells.

[1]  V. Syed,et al.  TGF‐β Signaling in Cancer , 2016, Journal of cellular biochemistry.

[2]  F. Jiao,et al.  EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic cancer , 2016, Oncotarget.

[3]  Stefan Enroth,et al.  Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target , 2016, Oncotarget.

[4]  T. Jiang,et al.  Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis , 2015, Oncotarget.

[5]  B. Klein,et al.  EZH2 in normal hematopoiesis and hematological malignancies , 2015, Oncotarget.

[6]  Eran Meshorer,et al.  Chromatin remodeling and bivalent histone modifications in embryonic stem cells , 2015, EMBO reports.

[7]  J. Pritchard,et al.  Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors , 2015, Oncotarget.

[8]  R. Paro,et al.  Trithorax and Polycomb group-dependent regulation: a tale of opposing activities , 2015, Development.

[9]  M. Harmsen,et al.  Enhancer of zeste homolog-2 (EZH2) methyltransferase regulates transgelin/smooth muscle-22α expression in endothelial cells in response to interleukin-1β and transforming growth factor-β2. , 2015, Cellular signalling.

[10]  Aaron T. L. Lun,et al.  Repression of Igf1 expression by Ezh2 prevents basal cell differentiation in the developing lung , 2015, Development.

[11]  C. Kang,et al.  DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. , 2015, Cancer letters.

[12]  P. Papageorgis TGFβ Signaling in Tumor Initiation, Epithelial-to-Mesenchymal Transition, and Metastasis , 2015, Journal of oncology.

[13]  Pierre-Olivier Angrand,et al.  Diverse involvement of EZH2 in cancer epigenetics. , 2015, American journal of translational research.

[14]  Amanda E. Jones,et al.  Snail2/Slug cooperates with Polycomb repressive complex 2 (PRC2) to regulate neural crest development , 2015, Development.

[15]  G. Jayandharan,et al.  Ezh2 mediated H3K27me3 activity facilitates somatic transition during human pluripotent reprogramming , 2015, Scientific Reports.

[16]  P. Angrand,et al.  Diverse involvement of EZH 2 in cancer epigenetics , 2015 .

[17]  D. Matei,et al.  TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells , 2014, Epigenetics.

[18]  K. Sundfeldt,et al.  TGF-β isoforms induce EMT independent migration of ovarian cancer cells , 2014, Cancer Cell International.

[19]  A. Díaz-López,et al.  A core microRNA signature associated with inducers of the epithelial‐to‐mesenchymal transition , 2014, The Journal of pathology.

[20]  H. Aburatani,et al.  Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders , 2013, The Journal of experimental medicine.

[21]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[22]  C. Plass,et al.  Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer , 2013, Nature Reviews Genetics.

[23]  J. Jonkers,et al.  Polycomb group gene Ezh2 regulates mammary gland morphogenesis and maintains the luminal progenitor pool , 2013, Stem cells.

[24]  Robert A. Weinberg,et al.  Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity , 2013, Cell.

[25]  Y. Shang,et al.  Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. , 2013, Experimental cell research.

[26]  M. Loda,et al.  EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent , 2012, Science.

[27]  Cun-Yu Wang,et al.  Histone Demethylase KDM6B Promotes Epithelial-Mesenchymal Transition* , 2012, The Journal of Biological Chemistry.

[28]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[29]  Christopher J. Schofield,et al.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response , 2012, Nature.

[30]  C. Heldin,et al.  Regulation of EMT by TGFβ in cancer , 2012, FEBS letters.

[31]  D. Matei,et al.  Tissue transglutaminase links TGF-β, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer , 2012, Oncogene.

[32]  R. Yang,et al.  Global mapping of H3K4me3 and H3K27me3 reveals chromatin state-based regulation of human monocyte-derived dendritic cells in different environments , 2012, Genes and Immunity.

[33]  S. Baylin,et al.  Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. , 2011, Cancer cell.

[34]  Qiang Yu,et al.  Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. , 2011, Molecular cell.

[35]  A. Feinberg,et al.  Genome-scale epigenetic reprogramming during epithelial to mesenchymal transition , 2011, Nature Structural &Molecular Biology.

[36]  Q. Cai,et al.  Enhancer of Zeste Homolog 2 Promotes the Proliferation and Invasion of Epithelial Ovarian Cancer Cells , 2010, Molecular Cancer Research.

[37]  Y. Zeng,et al.  EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. , 2010, Carcinogenesis.

[38]  R. Kuiper,et al.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.

[39]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[40]  Tracey M. Filzen,et al.  Tumorigenesis and Neoplastic Progression Targeted Overexpression of EZH 2 in the Mammary Gland Disrupts Ductal Morphogenesis and Causes Epithelial Hyperplasia , 2010 .

[41]  S. Dhanasekaran,et al.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer , 2008, Oncogene.

[42]  C. Sturgis,et al.  Transforming Growth Factor-β1, Transforming Growth Factor-β2, and Transforming Growth Factor-β3 Enhance Ovarian Cancer Metastatic Potential by Inducing a Smad3-Dependent Epithelial-to-Mesenchymal Transition , 2008, Molecular Cancer Research.

[43]  T. Veenstra,et al.  Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases , 2007, Proceedings of the National Academy of Sciences.

[44]  M. Fraga,et al.  The Polycomb group protein EZH2 directly controls DNA methylation , 2007, Nature.

[45]  Gema Moreno-Bueno,et al.  Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. , 2006, Cancer research.

[46]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[47]  Yi Zhang,et al.  The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. , 2004, Current opinion in genetics & development.

[48]  K. Sundfeldt Cell–cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule , 2003, Molecular and Cellular Endocrinology.

[49]  J. Thiery Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[50]  R. Derynck,et al.  TGF-β signaling in cancer – a double-edged sword , 2001 .

[51]  G. Berx,et al.  The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. , 2001, Molecular cell.

[52]  R. Derynck,et al.  TGF-beta signaling in cancer--a double-edged sword. , 2001, Trends in cell biology.

[53]  C. Marth,et al.  Regulation of transforming growth factor-beta secretion by human peritoneal mesothelial and ovarian carcinoma cells. , 2000, Cytokine.

[54]  K. Yasuda,et al.  Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA , 1987, Nature.